Tildacerfont

N/A

Report date: 2025/10/10 20:01:49
NME

Base Information

Drug NameTildacerfont
Drug Alias NameSPR-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCorticotropin-releasing factor receptor 1 antagonists
TargetsCorticotropin-releasing factor receptor 1
Therapy Area/IndicationsAdrenal Hyperplasia, CongenitalPolycystic Ovary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[20] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSpruce Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHMNC Brain Health GmbHSpruce Biosciences IncKaken Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsAdrenal Hyperplasia, CongenitalPolycystic Ovary Syndrome

Other Information

ATC CodeN/A
Related LinksN/A